Motco increased its holdings in shares of Novartis AG (NYSE:NVS) by 4.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,288 shares of the company’s stock after buying an additional 2,001 shares during the quarter. Motco’s holdings in Novartis were worth $4,572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also made changes to their positions in the company. Synovus Financial Corp grew its stake in Novartis by 0.7% during the 4th quarter. Synovus Financial Corp now owns 42,340 shares of the company’s stock valued at $4,007,000 after purchasing an additional 300 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in Novartis by 30.4% during the 4th quarter. Crossmark Global Holdings Inc. now owns 99,321 shares of the company’s stock valued at $9,405,000 after purchasing an additional 23,182 shares during the last quarter. ICW Investment Advisors LLC purchased a new stake in Novartis during the 4th quarter valued at about $183,000. Cedar Brook Financial Partners LLC acquired a new position in shares of Novartis in the 4th quarter valued at about $223,000. Finally, Hancock Whitney Corp acquired a new position in shares of Novartis in the 4th quarter valued at about $212,000. Hedge funds and other institutional investors own 10.61% of the company’s stock.
Several equities analysts have recently issued reports on NVS shares. ValuEngine raised Novartis from a “sell” rating to a “hold” rating in a report on Saturday, October 19th. Cowen reissued a “buy” rating and issued a $100.00 price objective on shares of Novartis in a report on Friday, October 25th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Novartis presently has a consensus rating of “Hold” and a consensus price target of $93.34.
The firm also recently declared an annual dividend, which will be paid on Thursday, March 12th. Investors of record on Wednesday, March 4th will be issued a $3.0425 dividend. This is a boost from Novartis’s previous annual dividend of $2.86. The ex-dividend date of this dividend is Tuesday, March 3rd. This represents a yield of 2%. Novartis’s dividend payout ratio is presently 35.11%.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.